Chemokine receptor binding heterocyclic compounds

US6750348B1 · kind B1 · utility

Assignee

• Anormed, Inc. · CA

Inventors

• Gary Bridger · Bellingham, US
• Renato Skerlj · Vancouver, CA
• Al Kaller · Vancouver, CA
• Curtis Harwig · White Rock, CA
• David Bogucki · Surrey, CA
• Trevor R. Wilson · Langley, CA
• Jason Crawford · Shelton, US
• Ernest J. McEachern · Burnaby, CA
• Bem Atsma · Abbotsford, CA
• Siqiao Nan · Richmond, CA
• Yuanxi Zhou · Langley, CA
• Dominique Schols · Herent, BE

Key dates

• Filing date: Mar 24, 2000
• Grant date: Jun 15, 2004
• Expiry date: Mar 24, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y═H;R1 to R7 may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6 alkyl;R8 is a substituted heterocyclic group or a substituted aromatic groupAr is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups;n and n′ are independently, 0-2;X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the abo…